Biogen Inc. (NASDAQ:BIIB)

An analysis of the valuation multiples from 2017 to 2021 reveals a divergence between profitability-based ratios and asset- or revenue-based ratios. While earnings and operating profit multiples exhibited a U-shaped trajectory, the ratios relating to sales and book value demonstrated a consistent downward trend throughout the period.

Price to Earnings (P/E)

The P/E ratio experienced significant volatility, beginning at 28.83 in 2017 and declining sharply to a low of 9.97 by 2019. After remaining relatively stable in 2020 at 10.02, the ratio rose substantially to 20.79 in 2021, indicating a marked increase in the market's valuation of earnings per share toward the end of the period.

Price to Operating Profit (P/OP)

The P/OP ratio followed a pattern similar to the P/E ratio but with less extreme fluctuations. It decreased from 13.70 in 2017 to a minimum of 8.34 in 2019, before recovering to 11.39 by 2021. This suggests a correlation between the market's valuation of operating profitability and overall net earnings.

Price to Sales (P/S)

A steady contraction is observed in the P/S ratio, which fell every year from 5.96 in 2017 to 2.95 in 2021. This persistent decline indicates that the market began assigning less value to each dollar of revenue generated by the company over the five-year window.

Price to Book Value (P/BV)

The P/BV ratio exhibited a consistent downward trend, decreasing from 5.80 in 2017 to 2.97 in 2021. This decline suggests a reduction in the premium the market was willing to pay over the company's accounting book value.

In summary, the data indicates that while the market's valuation relative to earnings and operating profits recovered in 2021, the valuation relative to sales and book value continued to diminish, reflecting a shift in the fundamental drivers of the stock's price multiple.

The financial trajectory between 2017 and 2021 is characterized by a significant divergence between earnings growth and market valuation, followed by a synchronized decline in both share price and earnings per share in the final period.

Share Price Trend

A general downward trajectory is observed in the share price over the five-year period. After remaining relatively stable between 2017 and 2019, the price experienced a notable decline starting in 2020, falling from a peak of 337.24 in 2019 to 220.17 by the end of 2021, representing a total decrease of approximately 35% from its high.

Earnings Per Share (EPS) Performance

Earnings exhibited strong growth in the early part of the period, rising from 12.00 in 2017 to a peak of 33.83 in 2019. However, this growth trend reversed sharply thereafter, with earnings dropping to 26.26 in 2020 and falling further to 10.59 in 2021, ending the period slightly below the 2017 baseline.

Price-to-Earnings (P/E) Ratio Dynamics

The P/E ratio underwent significant compression from 2017 to 2019, decreasing from 28.83 to 9.97. This indicates that while earnings were increasing, the market valuation multiple was contracting, suggesting a reduction in the premium investors were willing to pay per dollar of earnings. The ratio remained stable in 2020 at 10.02 but expanded sharply to 20.79 in 2021. This increase in the P/E ratio during 2021 occurred despite the decline in both share price and EPS, reflecting a relative valuation increase as earnings fell more precipitously than the share price.

The valuation trajectory between 2017 and 2021 reflects a period of significant volatility in both market pricing and operational efficiency, resulting in a non-linear movement of the Price to Operating Profit (P/OP) ratio.

Share Price Performance

A general decline in market valuation is observed over the five-year period. While the share price remained relatively stable between 2017 and 2019, fluctuating between 333.24 US$ and 346.00 US$, a sharp downward trend emerged after 2019, culminating in a low of 220.17 US$ by December 31, 2021.

Operating Profit per Share Trends

Operating profit per share exhibited a growth phase initially, rising from 25.26 US$ in 2017 to a peak of 40.46 US$ in 2019. This upward momentum reversed after 2019, with profit per share contracting to 29.87 US$ in 2020 and further declining to 19.33 US$ in 2021, representing a substantial reduction from the 2019 peak.

P/OP Ratio Analysis

The P/OP ratio followed a U-shaped pattern. From 2017 to 2019, the ratio compressed from 13.70 to 8.34, driven primarily by the rapid increase in operating profit per share which outpaced the movement of the share price. This indicates a period where the company became cheaper relative to its operational earnings. Conversely, from 2020 to 2021, the ratio expanded from 8.81 to 11.39. This expansion occurred because the decline in operating profit per share was more pronounced than the decline in the share price, leading to a relative increase in the valuation multiple despite the overall drop in absolute price and profit.

The valuation of Biogen Inc. as measured by the Price-to-Sales (P/S) ratio demonstrates a consistent and significant downward trend over the five-year period ending December 31, 2021.

Price-to-Sales Ratio Compression

A steady annual decline in the P/S ratio is observed, falling from 5.96 in 2017 to 2.95 in 2021. This represents a contraction of approximately 50.5% in the revenue multiple, suggesting a decrease in the market premium attributed to the company's sales over the observed period.

Sales per Share Performance

Sales per share experienced a growth phase from 2017 through 2020, rising from 58.02 to a peak of 88.26. This upward trajectory in revenue efficiency contributed to the compression of the P/S ratio during the early years of the analysis. However, this trend reversed in 2021, with sales per share declining to 74.72.

Share Price Volatility and Impact

The share price remained relatively stable between 2017 and 2019, holding within the 333.24 to 346.00 range. A notable downward shift occurred starting in 2020, with the price dropping to 263.25 and further declining to 220.17 by the end of 2021. Because both the share price and sales per share declined in 2021, the P/S ratio remained nearly flat, moving slightly from 2.98 to 2.95.

Between 2017 and 2021, a consistent contraction in the price-to-book value (P/BV) ratio is observed, reflecting a steady decline in market valuation relative to the company's accounting net assets.

Share Price Performance

The share price exhibited a general downward trajectory, decreasing from US$ 346.00 in 2017 to US$ 220.17 in 2021. Although a marginal increase was noted in 2019, the overall trend is characterized by a significant loss in market value per share over the five-year period.

Book Value per Share (BVPS) Trends

The book value per share showed a general upward trend, rising from US$ 59.62 in 2017 to US$ 74.14 by 2021. A temporary decrease occurred in 2020, where the value dipped to US$ 70.24, but the long-term movement indicates an increase in the net asset value attributable to each share.

Price to Book Value (P/BV) Compression

The P/BV ratio experienced a continuous annual decline, falling from 5.80 in 2017 to 2.97 in 2021. This represents a significant compression in the multiple, indicating that the market's willingness to pay a premium over the book value has diminished substantially.

The divergence between the declining share price and the generally increasing book value per share is the primary driver of the P/BV ratio's contraction. The reduction of the ratio by nearly half over the analyzed period suggests a marked shift in investor sentiment or a fundamental reassessment of the company's valuation relative to its balance sheet.